Skip to main content
OpenTrials
Completed

NCT Number: NCT03923400

Jejunoileal vs Gastric GIST in the Era of Imatinib.

Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib.

Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Disease-Free Survival Disease Attributes Overall Survival Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

David Ferreras

Murcia, 30120, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any kind of primary mesenchymal tumor of the gastrointestinal tract with a histomorphological and immunohistochemical (CD117 (+) and/or DOG1 (+)) profile consistent with GIST.

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. KIT Gene mutation

    Time frame: 15 years

    Number of patients with a molecular analysis positive for KIT mutation

  2. PDGFRA Gene mutation

    Time frame: 15 years

    Number of patients with a molecular analysis positive for PDGFRA mutation

  3. Expression of CD117

    Time frame: 15 years

    Number of patients with immunohistochemical expression of CD117

  4. Expression of DOG1

    Time frame: 15 years

    Number of patients with immunohistochemical expression of DOG1

  5. Recurrence

    Time frame: 15 years

    Number of patients with recurrence after treatment with tyrosinkin inhibitors.

  6. Deceased

    Time frame: 15 years

    Number of patients deceased during follow-up.

  7. Location

    Time frame: 15 years

    Location of the tumor (gastric o jejunoileal)

Sponsors and collaborators

Lead sponsor

Hospital Universitario Virgen de la Arrixaca

Other

Registry information

Official study title

Characteristics and Prognosis of Jejunoileal Gastrointestinal Stromal Tumors (GISTs) in the Era of Imatinib. A Comparative Retrospective Study With Gastric GISTs.

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Apr 22, 2019
Registry last updated
Apr 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.